Arcus Biosciences, Inc.

Equities

RCUS

US03969F1093

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:02 2024-04-26 pm EDT			5-day change	1st Jan Change
15.55 ^USD	+5.57%		+6.58%	-18.59%

Mar. 12	Transcript : Arcus Biosciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 02:35 PM
Feb. 29	Arcus Biosciences Insider Sold Shares Worth $1,177,967, According to a Recent SEC Filing	MT

Arcus Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023

February 21, 2024 at 04:05 pm EST

Arcus Biosciences, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 31 million compared to USD 34 million a year ago. Net loss was USD 81 million compared to USD 67 million a year ago.

Basic loss per share from continuing operations was USD 1.08 compared to USD 0.93 a year ago.

Latest news about Arcus Biosciences, Inc.

Transcript : Arcus Biosciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 02:35 PM	Mar. 12
Arcus Biosciences Insider Sold Shares Worth $1,177,967, According to a Recent SEC Filing	Feb. 29	MT
Arcus Biosciences Insider Sold Shares Worth $543,187, According to a Recent SEC Filing	Feb. 29	MT
Transcript : Arcus Biosciences, Inc. Presents at Citi 2024 Virtual Oncology Leadership Summit, Feb-22-2024 11:00 AM	Feb. 22
Transcript : Arcus Biosciences, Inc., Q4 2023 Earnings Call, Feb 21, 2024	Feb. 21
Earnings Flash (RCUS) ARCUS BIOSCIENCES Reports Q4 Revenue $31M	Feb. 21	MT
Arcus Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 21	CI
Gilead and Arcus Announce Amended Collaboration Agreement	Jan. 31	CI
Global markets live: WPP UPS GM, Super Micro Computer, Microsoft...	Jan. 30
Mizuho Adjusts Arcus Biosciences' Price Target to $42 From $51, Keeps Buy Rating	Jan. 30	MT
Wedbush Lowers Arcus Biosciences' PT to $30 From $36 After Announced Plans to Discontinue Enrollment for Phase 3 ARC-10 Study; Keeps Outperform Rating	Jan. 30	MT
North American Morning Briefing : Microsoft Kicks Off Big Tech Bonanza	Jan. 30	DJ
Gilead Sciences raises stake in cancer-centric Arcus Biosciences to 33%	Jan. 29	RE
Gilead Sciences, Arcus Biosciences Amend Collaboration Agreement to Accelerate Joint Development Programs	Jan. 29	MT
Arcus Biosciences, Inc. announced that it expects to receive $320.000016 million in funding from Gilead Sciences, Inc.	Jan. 28	CI
Arcus Biosciences Says Phase 1b Study of Pancreatic Cancer Therapy Showed 'Promising Overall Survival Data'	Jan. 17	MT
Arcus Biosciences, Inc. Announces Data from A Phase 1B Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naive Metastatic Pancreatic Cancer	Jan. 16	CI
Exelixis, Inc. and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with Ab521 in Patients with Advanced Renal Cell Carcinoma	Dec. 04	CI
Morgan Stanley Cuts Price Target on Arcus Biosciences to $35 From $38, Maintains Overweight Rating	Nov. 13	MT
Cantor Fitzgerald Adjusts Arcus Biosciences' Price Target to $36 From $46, Maintains Overweight Rating	Nov. 08	MT
Transcript : Arcus Biosciences, Inc., Q3 2023 Earnings Call, Nov 07, 2023	Nov. 07
Earnings Flash (RCUS) ARCUS BIOSCIENCES Posts Q3 Revenue $32M, vs. Street Est of $27.6M	Nov. 07	MT
Arcus Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announces New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI Cancers	Nov. 06	CI
Arcus Biosciences Insider Sold Shares Worth $427,166, According to a Recent SEC Filing	23-09-26	MT

Chart Arcus Biosciences, Inc.

Duration

Period

More charts

Company Profile

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Arcus Biosciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

15.55 USD

Average target price

38.89 USD

Spread / Average Target

+150.09%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ARCUS BIOSCIENCES, INC.	-18.59%	1.41B
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research